Diclofenac

證據等級: L5

預測適應症: 10 個

Diclofenac: From Pain and Inflammatory Conditions to Juvenile Idiopathic Arthritis

One-Sentence Summary

Diclofenac is a well-established non-steroidal anti-inflammatory drug (NSAID) widely used for pain relief and inflammatory conditions including rheumatic diseases in adults. The TxGNN model predicts it may be effective for Juvenile Idiopathic Arthritis (JIA), with 2 clinical trials and 18 publications currently supporting this direction.

Note: This is a multi-indication Evidence Pack (TW-DB00586-multi) covering 10 predicted indications. Nine of these (ranks 1–8, 10) are classified as L5 evidence with a "Hold" recommendation due to absent mechanistic linkage and no supporting clinical data. This report focuses on Juvenile Idiopathic Arthritis (rank 9), the sole indication with actionable evidence (L3) and a "Proceed with Guardrails" recommendation.

Quick Overview

Item	Content
Original Indication	Pain and inflammatory conditions (no local registrations available; based on known pharmacology)
Predicted New Indication	Juvenile Idiopathic Arthritis (JIA)
TxGNN Prediction Score	99.25%
Evidence Level	L3
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Diclofenac is a non-selective COX-1/COX-2 inhibitor. By blocking cyclooxygenase enzymes, it reduces prostaglandin E2 (PGE2) synthesis, thereby decreasing the release of inflammatory mediators from synovial tissue and alleviating joint swelling and pain. Although detailed mechanistic data from the local package insert was not retrieved in this Evidence Pack (DG002), Diclofenac's anti-inflammatory pathway is extensively documented across four decades of international literature.

Juvenile Idiopathic Arthritis (JIA) is defined by persistent synovial inflammation arising in children under 16 years of age. The pathological core—chronic synovitis driven by immune dysregulation—directly aligns with Diclofenac's mechanism of action. NSAIDs, including Diclofenac at approximately 2 mg/kg/day, have served as first-line symptomatic therapy in JIA since the late 1970s. Multiple published studies confirm effectiveness and tolerability in the paediatric population across polyarticular and seronegative subtypes of juvenile chronic arthritis.

Notably, the literature confirms that Diclofenac is already licensed in multiple jurisdictions for children over 1 year of age for the treatment of juvenile rheumatoid arthritis—making this TxGNN prediction not only biologically credible but also supported by international regulatory precedent. The model score of 99.25% reflects this strong mechanistic and clinical alignment.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00688545	N/A (Observational)	Terminated	275	SINCERE Registry: prospective, multi-centre safety study comparing NSAIDs (including Diclofenac) vs. celecoxib in JIA patients in real-world clinical practice. Terminated early, but captures meaningful safety signals for NSAID use in this paediatric population.
NCT05871086	Phase 2/3	Unknown	60	Coenzyme Q10 supplementation in JIA patients; NSAIDs used as standard background therapy, providing contextual data on JIA disease burden and current management landscape.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3052965	1988	Crossover RCT	Clinical and Experimental Rheumatology	Single-blind crossover study in 28 children with seronegative JCA: diclofenac 2 mg/kg/day vs. naproxen vs. tolmetin over 12 weeks; all three showed comparable clinical and laboratory improvement with similar tolerability.
6361986	1983	Clinical Trial	Scandinavian Journal of Rheumatology	Pharmacokinetics and efficacy of diclofenac sodium in children aged 2–7 with JRA; established plasma level profiles and renal elimination parameters to guide paediatric dosing of 25 mg enteric-coated tablets.
2235663	1990	Clinical Study	La Pediatria Medica e Chirurgica	Open non-comparative study in 26 patients aged 2–16 with polyarticular JCA; Diclofenac sodium confirmed effective anti-inflammatory and analgesic effects equivalent to adult outcomes.
10756785	1997	Comparative Study	Revista Medico-Chirurgicala	8-year comparative study of NSAIDs in 100 children with JCA; diclofenac group demonstrated sustained clinical response at 2, 4, and 6 months and up to 3 years of follow-up.
8422565	1993	Review	British Journal of Rheumatology	Comprehensive review of NSAID use in paediatric rheumatic diseases; diclofenac identified as equal in efficacy and tolerability to ibuprofen, naproxen, and tolmetin for JIA joint symptom control, with a superior profile to salicylates.
1884567	1991	PK/PD Study	Clinical Pharmacokinetics	Pharmacokinetics of drugs used in juvenile arthritis including Diclofenac; provides comprehensive dosing guidance for the paediatric rheumatology population.
11735667	2001	Comparative Review	Paediatric Drugs	Risks and benefits of NSAIDs vs. paracetamol in children; JIA cited as a key therapeutic indication with COX inhibition mechanism reviewed for the paediatric context.
17474954	2007	Survey	Paediatric Anaesthesia	Survey of paediatric anaesthetists across Great Britain and Ireland; explicitly confirms that Diclofenac is currently licensed for children over 1 year of age for juvenile rheumatoid arthritis treatment in these jurisdictions.
723822	1978	Clinical Study	Minerva Pediatrica	One of the earliest clinical reports of sodium Diclofenac (Voltaren) in infantile rheumatoid arthritis; establishes historical basis for this paediatric indication.
6761640	1982	Clinical Study	Pediatriia	Clinical evaluation of Voltaren (Diclofenac) in children with rheumatoid arthritis; early Eastern European clinical experience supporting the JIA indication.

Singapore Market Information

Diclofenac currently has 0 approved product registrations in Singapore's Health Sciences Authority (HSA) registry and is not marketed in this jurisdiction.

International reference labels (FDA, EMA, or TFDA) should be consulted for full prescribing information. Multiple international markets have approved Diclofenac for juvenile rheumatoid arthritis, which may serve as a regulatory anchor for a future Singapore submission.

Safety Considerations

Please refer to the package insert for safety information.

Key warnings and contraindications data were unavailable in this Evidence Pack (DG001 — Blocking). This gap must be resolved before formal safety assessment can proceed. Given the absence of local registration, the FDA, EMA, or TFDA label should be retrieved and reviewed. Known class-level safety concerns for NSAIDs include gastrointestinal toxicity, cardiovascular risk (with long-term use), and renal impairment — all of which require particular attention in the paediatric JIA population on chronic therapy.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Diclofenac's COX-1/COX-2 inhibitory mechanism directly targets the synovial inflammation that defines JIA, and clinical evidence spanning over four decades confirms its use and tolerability in paediatric arthritis populations. The drug is already approved for juvenile rheumatoid arthritis in multiple international jurisdictions (UK, EU, several others), providing strong regulatory precedent — even though Singapore registration data is currently absent.

To proceed, the following is needed:

Retrieve the full package insert from an international source (FDA, EMA, or TFDA) to complete key warnings and contraindications assessment — this is a Blocking data gap (DG001)
Obtain complete MOA data via DrugBank API (DG002 — High priority) to strengthen mechanistic documentation
Confirm age-appropriate formulation availability (e.g., dispersible tablet, oral suspension) for the JIA target population, particularly younger children
Conduct an HSA registration gap analysis using existing international JIA approvals as the regulatory anchor for a potential Singapore submission
Review current JIA treatment guidelines (ACR 2021, EULAR 2023) to position Diclofenac appropriately relative to modern biologics (TNF inhibitors, IL-6 inhibitors, JAK inhibitors), particularly for the initial symptomatic management phase
Design a long-term safety monitoring plan addressing GI, cardiovascular, and renal parameters specific to the paediatric chronic use setting
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.